Nasal Delivery of Peptides and Proteins with Chitosan and Related Mucoadhesive Polymers

Peptide and Protein Delivery

Volumn , Issue , 2011, Pages 47-68

  Ritthidej, Garnpimol C ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882468769     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384935-9.10003-3     Document Type: Chapter

References (95)

1. M.I. Ugwoke, R.U. Agu, N. Verbeke and R. Kinget (2005) Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv. Drug Deliv. Rev. 57 1640-1655.
2. L. Illum (2002) Nasal drug delivery: New developments and strategies. Drug Discov. Today 7 1184-1189.
3. H.R. Costantino, L. Illum, G. Brandt, P.H. Johnson and S.C. Quay (2007) Intranasal delivery: Physicochemical and therapeutic aspects. Int. J. Pharm. 337 1-24.
4. P.H. Johnson and S.C. Quay (2005) Advances in nasal drug delivery through tight junction technology. Expert Opin. Drug Deliv. 2 281-298.
5. P. Arora, S. Sharma and S. Garg (2002) Permeability issues in nasal drug delivery. Drug Discov. Today 7 967-975.
6. A.-L. Cornaz and P. Buri (1994) Nasal mucosa as an absorption barrier. Eur. J. Pharm. Biopharm. 40 261-270.
7. C.R. Behl, H.K. Pimplaskar, A.P. Sileno, W.J. Xia, W.J. Gries, J.C. de Meireles, et al. (1998) Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv. Drug Deliv. Rev. 29 117-133.
8. N. Migand, M. Pedersen and M.H. Nielsen (1982) Morphology of the upper airway epithelium. D.F. Proctor, I.B. Andersen (Eds) The Nose – Upper Airway Physiology and the Atmospheric Environment New York: Elsevier Science Publishing Co. 71-97.
9. S.C. Chen, K. Eiting, K. Cui, A.K. Leonard, D. Morris, C.Y. Li, et al. (2006) Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery. J. Pharm. Sci. 95 1364-1371.
10. E. Marttin, N. Schipper, J. Verhoef and W.H.M. Merkus (1998) Nasal mucociliary clearance as a factor in nasal drug delivery. Adv. Drug Deliv. Rev. 29 13-38.
11. M.A. Longer and J.R. Robinson (1986) Fundamental aspects of bioadhesion. Pharm. Int. 5 114-117.
12. P. Roussel, G. Lamblin, M. Lhermitte, N. Houdret, J.J. Lafitte, J.M. Perini, et al. (1998) The complexity of mucins. Biochimie. 70 1471-1482.
13. P.O. Glantz, T. Arnebrant, T. Nylander and R.E. Baier (1999) Bioadhesion – A phenomenon with multiple dimensions. Acta Odontol. Scand. 57 238-241.
14. H. Park and J.R. Robinson (1985) Physicochemical properties of water insoluble polymers important to mucin/epithelial adhesion. J. Control. Release 2 47-57.
15. L. Jiang, L. Gao, X. Wang, L. Tang and J. Ma (2010) The application of mucoadhesive polymers in nasal drug delivery. Drug Devel. Ind. Pharm. 36 323-336.
16. N.A. Peppas and P.A. Buri (1985) Surface, interfacial and molecular aspects of polymers bioadhesion on soft tissue. J. Control. Release 2 257-275.
17. L. Illum, N.F. Farraj and S.S. Davis (1994) Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. 11 1186-1189.
18. T. Cerchiara, B. Luppi, F. Bigucci and V. Zecchi (2003) Chitosan salts as nasal sustained delivery systems for peptidic drugs. J. Pharm. Pharmacol. 55 1623-1627.
19. M. Hinchcliffe, I. Jabbal-Gill and A. Smith (2005) Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep. J. Pharm. Pharmacol. 57 681-687.
20. L. Illum, P. Watts, A.N. Fisher, I. Jabbal-Gill and S.S. Davis (2000) Novel chitosan based delivery systems for nasal administration of an LHRH-analogue. STP Pharma. 10 89-94.
21. P. Tengamnuay, A. Sahamethapat, A. Sailasuta and A. Mitra (2000) Chitosans as nasal absorption enhancers of peptides: Comparison between free amine chitosans and soluble salts. Int. J. Pharm. 197 53-67.
22. D. Mei, S. Mao, W. Sun, Y. Wang and T. Kissel (2008) Effect of chitosan structure properties and molecular weight on the intranasal absorption of tetramethylpyrazine phosphate in rats. Eur. J. Pharm. Biopharm. 70 874-881.
23. S. Yu, Y. Zhao, F. Wu, X. Zhang, W. Lu, H. Zhang, et al. (2004) Nasal insulin delivery in the chitosan solution: In vitro and in vivo studies. Int. J. Pharm. 81 11-23.
24. A.M. Dyer, M. Hinchcliffe, P. Watts, J. Castile, I. Jabbal-Gill, R. Nankervis, et al. (2002) Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm. Res. 19 998-1008.
25. J. Varshosaz, H. Sadrai and R. Alinagari (2004) Nasal delivery of insulin using chitosan microspheres. J. Microencap. 21 761-774.
26. L. Illum (2007) Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems? J. Pharm. Sci. 96 473-483.
27. S. Harikarnpakdee, N. Sutanthavibul, V. Lipipun and G.C. Ritthidej (2006) Spray dried mucoadhesive microspheres: Preparation, and transport through nasal cell monolayer. AAPS Pharm. Sci. Tech. 7 E79-E88.
28. C. Kusonwiriyawong, W. Pichayakorn, V. Lipipun and G.C. Ritthidej (2009) Retained integrity of protein encapsulated in spray-dried chitosan microparticles. J. Microencap. 26 111-121.
29. M.W. Thanou, J.C. Verhoef, S.G. Romeijn, J.F. Nagelkerke, F.W. Merkus and H.E. Junginger (1999) Effects of N-trimethyl chitosan chloride, a novel absorption enhancer, on Caco-2 intestinal epithelia and the ciliary beat frequency of chicken embryo trachea. Int. J. Pharm. 185 73-82.
30. D. Sakloetsakun, G. Perera, J. Hombach, G. Millotti and A. Bernkop-Schnürch (2010) The impact of vehicles on the mucoadhesive properties of orally administrated nano particles: A case study with chitosan-4-thiobutylamidine conjugate. AAPS Pharm Sci Tech. 11 1185-1192.
31. M. Prabaharan and S. Gong (2008) Novel thiolated carboxymethyl chitosan-g-β-cyclodextrin as mucoadhesive hydrophobic drug delivery carriers. Carbohyd. Polym. 73 117-125.
32. E. Gavini, G. Rassu, C. Muzzarelli, M. Cossu and P. Giunchedi (2008) Spray dried microspheres based on methylpyrrolinone chitosan as new carrier for nasal administration of metoclopramide. Eur. J. Pharm. Biopharm. 68 245-253.
33. P. Calvo, C. Remunan-Lopez, J.L. Vila-Jato and M.J. Alonso (1997) Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carries for proteins and vaccines. Pharm. Res. 14 1431-1436.
34. J.H. Hamman, M. Stander and A.F. Kotze (2002) Effect of the degree of quaternisation of N-trimethyl chitosan chloride on absorption enhancement: In vivo evaluation in rat nasal epithelia. Int. J. Pharm. 232 235-242.
35. A.H. Krauland, D. Guggi and A. Bernkop-Schnurch (2006) Thiolated chitosan microparticles: A vehicle for nasal peptide drug delivery. Int. J. Pharm. 307 270-277.
36. X. Zhang, H. Zhang, Z. Wu, Z. Wang, H. Niuand and C. Li (2008) Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles. Eur. J. Pharm. Biopharm. 68 526-534.
37. A. Jindapattanakit, P. Peungvicha, A. Sailasuta, T. Kissel and V.B. Junyaprasert (2010) Nasal absorption and local tissue reaction of insulin nanocomplexes of trimethyl chitosan derivatives in rats. J. Pharm. Pharmacol. 62 583-591.
38. R.F. Tester, J. Karkalas and X. Qi (2004) Starch – composition, fine structure and architecture. J. Cereal Sci. 39 151-165.
39. P. Edman, E. Bjork and L. Ryden (1992) Microspheres as a nasal delivery system for peptide drugs. J. Control. Release 21 165-172.
40. E. Björk and P. Edman (1988) Degradable starch microspheres as a nasal delivery system for insulin. Int. J. Pharm. 47 233-238.
41. L. Illum, A.N. Fisher, I. Jabbal-Gill and S.S. Davis (2001) Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int. J. Pharm. 222 109-119.
42. A.K. Jain, R.K. Khar, F.J. Ahmed and P.V. Diwan (2008) Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur. J. Pharm. Biopharm. 69 426-435.
43. H. Blanco-Fuente, S. Anguiano, F.J. Otero-Espinar and J. Balnco-Mendez (1996) In vitro bioadhesion of carbopol hydrogels. Int. J. Pharm. 142 169-174.
44. G. Rathnam, N. Narayanan and R. Ilavarasan (2008) Carbopol-based gels for nasal delivery of progesterone. AAPS Pharm. Sci. Tech. 9 1078-1082.
45. Y. Suzuki and Y. Makino (1999) Mucosal drug delivery using cellulose derivatives as a functional polymer. J. Control. Release 62 101-107.
46. D. Teshima, A. Yamauchi, K. Makino, Y. Kataoka, Y. Arita, H. Nawata, et al. (2002) Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers. Int. J. Pharm. 233 61-66.
47. T. Matsuyama, T. Morita, Y. Horikiri, H. Yamahara and H. Yoshino (2007) Influence of fillers in powder formulations containing N-acetyl-l-cysteine on nasal peptide absorption. J. Control. Release 120 88-94.
48. A. Bernkop-Schnurch, C.E. Kast and M.F. Richter (2001) Improvement in the mucoadhesive properties of alginate by the covalent attachment of cysteine. J. Control. Release 71 277-285.
49. K. Morimoto, H. Katsumata, T. Yabuta, K. Iwanaga, M. Kakemi, Y. Tabata, et al. (2001) Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin. Eur. J. Pharm. Sci. 13 179-185.
50. J. Wang, S. Sakai, Y. Deguchi, D. Bi, Y. Tabata and K. Morimoto (2002) Aminated gelatin as a nasal absorption enhancer for peptide drugs: Evaluation of absorption enhancing effect and nasal mucosa perturbation in rats. J. Pharm. Pharmacol. 54 181-188.
51. T. Seki, H. Kanbayashi, S. Chono, Y. Tabata and K. Morimoto (2007) Effects of a sperminated gelatin on the nasal absorption of insulin. Int. J. Pharm. 338 213-218.
52. K. Ohtake, T. Maeno, H. Ueda, H. Natsume and Y. Moritomo (2003) Poly-l-Argenine predominantly increases the paracellular permeability of hydrophilic macromolecules across rabbit nasal epithelium. in vivo. Pharm. Res. 20 153-160.
53. M. Miyamoto, H. Natsume, I. Satoh, K. Ohtake, M. Yamaguchi, D. Kobayashi, et al. (2001) Effect of poly-l-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Int. J. Pharm. 226 127-138.
54. K. Morimoto, H. Yamaguchi, Y. Iwakura, K. Morisaka, Y. Ohashi and Y. Nakai (1991) Effects of viscous hyaluronate sodium solutions on the nasal absorption of vasopressin and an analogue. Pharm. Res. 8 471-474.
55. L. Illum, N.F. Farraj, A.N. Fisher, I. Jabbal-Gill, M. Miglietta and L.M. Benedetti (1994) Hyaluronic acid ester microspheres as a nasal delivery system for insulin. J. Control. Release 29 133-141.
56. C.-M. Lehr (2000) Lectin-mediated drug delivery: The second generation of bioadhesives. J. Control. Release 65 19-29.
57. E.-S. Khafagy, M. Morishita, K. Isowa, J. Imai and K. Takayama (2009) Effect of cell penetrating peptides on the nasal absorption of insulin. J. Control. Release 133 103-108.
58. M.D. Hornof, C.E. Kast and A. Bernkop-Schnurch (2003) In vitro evaluation of the viscoelastic properties of chitosan–thioglycolic acid conjugates. Eur. J. Pharm. Biopharm. 55 185-190.
59. S. Park, Y.K. Oh, H. Yoon, J.M. Kim and C.K. Kim (2002) In situ gelling and mucoadhesive polymer vehicles for controlled intranasal delivery of plasmid DNA. J. Biomed. Mater. Res. 59 144-151.
60. T.-W. Chung, D.-Z. Liu and J.-S. Yang (2010) Effect of interpenetration of thermo-sensitive gels by crosslinking of chitosan on nasal delivery of insulin: In vitro characterization and in vivo study. Carbohyd. Polym. 82 316-322.
61. J. Wu, W. Wei, L.-Y. Wang, Z.-G. Su and G.-H. Ma (2007) A thermosensitive hydrogel based on quaternized chitosan and poly(ethylene glycol) for nasal drug delivery system. Biomaterials 28 2220-2232.
62. E. Adriaens, D. Ameye, M.M. Dhondt, P. Foreman and J.P. Remon (2003) Evaluation of the mucosal irritation potency of co-spray dried Amioca/poly(acrylic acid) and Amioca/Carbopol 974P mixtures. J. Control. Release 88 393-399.
63. C. Callens and J.P. Remon (2000) Evaluation of starch–maltodextrin–Carbopol 974 P mixtures for the nasal delivery of insulin in rabbits. J. Control. Release 66 215-220.
64. S.T. Lim, G.P. Martin, D.J. Berry and M.B. Brown (2000) Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. J. Control. Release 66 281-292.
65. X. Wang, C. Zheng, Z. Wu, T. Teng, X. Zhang and C. Li (2009) Chitosan-NAC nanoparticles as a vehicle for nasal absorption enhancement of insulin. J. Biomed. Mater. Res. B. 88 150-161.
66. E. Pringels, C. Vervaet, B. Verbeeck, P. Foreman and J.P. Remon (2008) The addition of calcium ions to starch/carbopol mixture enhances the nasal bioavailability of insulin. Eur. J. Pharm. Biopharm. 68 201-206.
67. C. Callens, J. Ceulemans, A. Ludwig, P. Foreman and J.P. Remon (2003) Rheological study on mucoadhesivity of some nasal powder formulations. Eur. J. Pharm. Biopharm. 55 323-328.
68. D.S. Viswanath, T.K. Ghosh, D.H.L. Prasad, N.V.K. Dutt and K.Y. Rani (2007) Viscosity of Liquids: Theory, Estimation, Experiment, and Data. Dordrecht, The Netherlands: Springer
69. A. Ahuja, R.K. Khar and J. Ali (1997) Mucoadhesive drug delivery systems. Drug Dev. Ind. Pharm. 23 489-515.
70. K.V.R. Rao and P. Buri (1989) A novel in situ method to test polymers and coated microparticles for bioadhesion. Int. J. Pharm. 52 265-270.
71. V. Grabovac, D. Guggi and A. Bernkop-Schurch (2005) Comparison of the mucoadhesive properties of various polymers. Adv. Drug Deliv. Rev. 57 1713-1723.
72. C.-P. Lee, R.L.A. de Vrueh and P.L. Smith (1997) Selection of development candidates based on in vitro permeability measurements. Adv. Drug Deliv. Rev. 23 47-62.
73. C. Wadell, E. Björk and O. Camber (1999) Nasal drug delivery – evaluation of an in vitro model using porcine nasal mucosa. Eur. J. Pharm. Sci. 7 197-203.
74. S.H. Randell, L. Walstad, U.E. Schwab, B.R. Grubb and J.R. Yankaskas (2001) Isolation and culture of airway epithelial cells from chronically infected human lungs. In vitro Cell Dev. Biol. – Anim. 37 480-489.
75. D.C. Gruenert, W.E. Finkbeiner and J.H. Widdicombe (1995) Culture and transformation of human airway epithelial cells. Am. J. Physiol. 268 L347-L360.
76. M.C. Schmidt, H. Peter, S.R. Lang, G. Ditzinger and H.P. Merkle (1998) In vitro cell models to study nasal mucosal permeability and metabolism. Adv. Drug Deliv. Rev. 29 51-79.
77. U. Werner and T. Kissel (1995) Development of a human nasal epithelial cell culture model and its suitability for transport and metabolism studies under in vitro conditions. Pharm. Res. 12 565-571.
78. A. De Fraissinette, R. Brun, H. Felix, J. Vonderscher and A. Rummelt (1995) Evaluation of the human cell line RPMI 2650 as an in vitro nasal model. Rhinology 33 194-198.
79. K.A. Foster, M.L. Avery, M. Yazdanian and K.L. Audus (2000) Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int. J. Pharm. 208 1-11.
80. A. Wengst and S. Reichl (2010) RPMI2650 epithelial model and three dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies. Eur. J. Pharm. Biopharm. 74 290-297.
81. R.U. Agu, M. Jorissen, R. Kinget, N. Verbeke and P. Augustijns (2002) Alternatives to in vivo nasal toxicological screening for nasally-administered drugs. STP Pharm. Sci. 12 13-22.
82. P. Markus, S.G. Romeijn, J.C. Verhoef, F.W. Merkus and P.F. Schonwenburg (2001) Classification of cilio-inhibiting effects of nasal drops. Laryngoscope 111 595-602.
83. T.J. Aspden, J.D.T. Mason, N.S. Jones, J. Lowe, O. Skaugrud and L. Illum (1997) Chitosan as a nasal delivery system: The effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J. Pharm. Sci. 86 509-513.
84. M.I. Ugwoke, R.U. Agu, M. Jorissen, P. Augustijns, R. Sciot, N. Verbeke, et al. (2000) Toxicological investigations of the effects of carboxymethylcellulose on ciliary beat frequency of human nasal epithelial cells in primary suspension culture and in vivo on rabbit nasal mucosa. Int. J. Pharm. 205 43-51.
85. M.I. Ugwoke, R.U. Agu, M. Jorissen, P. Augustijns, R. Sciot, N. Verbeke, et al. (2000) Nasal toxicological investigations of Carbopol 971P formulation of apomorphine: Effects on ciliary beat frequency of human nasal primary cell culture and in vivo on rabbit nasal mucosa. Eur. J. Pharm. Sci. 9 387-396.
86. C. Callens, E. Adriaens, K. Dierckens and J.P. Remon (2001) Toxicological evaluation of a bioadhesive nasal powder containing a starch and carbopol 974P on rabbit nasal mucosa and slug mucosa. J. Control. Release 76 81-91.
87. S. Dimova, M.E. Brewster, M. Noppe, M. Jorissen and P. Augustijns (2005) The use of human nasal in vitro cell systems during drug discovery and development. Toxicol. Vitro 19 107-122.
88. T.K. Vyas, A. Shahiwala, S. Marathe and A. Misra (2005) Intranasal drug delivery for brain targeting. Curr. Drug Deliv. 2 165-175.
89. C.L. Graff and G.M. Pollack (2005) Nasal drug administration: Potential for targeted central nervous system delivery. J. Pharm. Sci. 94 1187-1195.
90. S.V. Dhuria, L.R. Hanson and W.H. Prey II (2010) Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J. Pharm. Sci. 99 1654-1673.
91. S. Horvat, A. Feher, H. Wolburg, P. Sipos, S. Veszelka, A. Toth, et al. (2009) Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue. Eur. J. Pharm. Biopharm. 72 252-259.
92. R.G. Thorne, G.J. Pronk, V. Padmanabhan and W.H. Frey (2004) Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127 481-496.
93. S.R.K. Vaka, S.M. Sammeta, L.B. Day and S.N. Murthy (2009) Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J. Pharm. Sci. 98 3640-3646.
94. W.A. Banks, M.J. During and M.L. Niehoff (2004) Brain uptake of the glucagon-like peptide-1 antagonist exendin(9–39) after intranasal administration. J. Pharmacol. Exp. Ther. 309 469-475.
95. R.S. Kaye, T.S. Purwal and O.H. Alpar (2009) Development and testing of particulate formulation for nasal delivery of antibodies. J. Control. Release 135 127-135.